Posted by Michael Wonder on 05 Aug 2023
Basilea announces submission of a new drug application to the US FDA for its antibiotic ceftobiprole
4 August 2023 - Seeking approval for Staphylococcus aureus bacteraemia, acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Basilea Pharmaceutica announced today that it has submitted a new drug application to the US FDA.
